Monotherapy with either MLP or the anti-PD-1 antibody demonstrated a low ability to induce an anti-tumor immune response, whereas combination therapy (MLP plus anti-PD-1 antibody) improved anti-tumor immune response, resulting in tumor growth control and increased animal survival. Here, PDCD1 is linked to neoplasm.